Home

EDV
EDV
EDV
Covid EDV Vax Booster
We need healthy heroes to volunteer for our vaccine trial against COVID 19

We are looking for volunteers who:
• are 18 years and older
• are in good health
• have been vaccinated or recovered from COVID-19 at least 4 months prior
• or have never received a vaccine

For more information, please contact our Clinical Trials Team

For more information
MORE INFO
EDVs
The EDV nanocell is a first-in-class cyto-immunotherapy platform targeting the tumor directly and leveraging the patient’s own immune system.
Careers
Currently Recruiting
READ MORE
previous arrowprevious arrow
next arrownext arrow
Shadow

 

Breaking News

 

Channel 9 News – 27th June 2022

EnGeneIC develops world-first nanocellular anti-COVID-19 vaccine that defeats mutant viruses and stimulates a broad anti-viral response

Click for full story

Works against mutant strains including Delta & Omicron. No need for refrigeration during transport and storage. No added stabilisers or chemicals. Safety and immune response clinical trial recruiting now in Melbourne, Sydney & Perth to follow. Efficacy trial planned for USA.

For more information about becoming a volunteer for the COVID-19 EDV™ Vaccine Trial contact our Clinical Trials Team.

Learn more about EnGeneIC Dream Vector (EDV™) Nanocell platform technology

Publication in prestigious scientific journal, Cancer Cell, highlighting the ability of EDV™ Nanocells to mount dual assault on Cancer Cells

EDV™ Technology Stimulates Both Innate and Adaptive Immune Response and Confers Long-Term Survival

Abstract accepted  to the Annual Meeting of the American Society of Clinical Oncology 2020

Abstract Demonstrates Promising Early Results from Phase I/IIa study in Patients with Recurrent, Metastatic Pancreatic Cancer.